Emilio Blanco-López , Jorge Martínez-del Río , Alba López-Calles , Martín Negreira-Caamaño , Daniel Águila-Gordo , Pablo Soto-Martín , Maria Maeve Soto-Pérez , Andrez Felipe Cubides-Novoa , Maria Gonzalez-Barderas , Ignacio Sánchez-Pérez , Jesús Piqueras-Flores
{"title":"Cardiac amyloidosis and red flags: natural history and its impact in morbimortality","authors":"Emilio Blanco-López , Jorge Martínez-del Río , Alba López-Calles , Martín Negreira-Caamaño , Daniel Águila-Gordo , Pablo Soto-Martín , Maria Maeve Soto-Pérez , Andrez Felipe Cubides-Novoa , Maria Gonzalez-Barderas , Ignacio Sánchez-Pérez , Jesús Piqueras-Flores","doi":"10.1016/j.medcle.2025.01.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Red flags (RF) are typical cardiac and extracardiac manifestations that may precede the definitive diagnosis of cardiac amiloidosis (CA) by several years, playing a pivotal role in the early diagnosis of the disease. The principal aim of the research was to determine the chronology of onset of RF throughout the natural history of CA as well as its prognostic influence.</div></div><div><h3>Patients and methods</h3><div>Observational, retrospective inquiry of consecutive patients with a definitive diagnosis of CA in a terciary hospital centre in Ciudad Real (Spain) between February 2016 and December 2023. We defined 21 RF and 3 adverse clinical events, establishing the date of occurrence of each of them.</div></div><div><h3>Results</h3><div>102 patients (81,6 ± 7,7 years; 84,3% males) with a diagnosis of CA (89,2% TTR; 10,8% AL) were included. The prevalence of RF was very high (8,4 ± 2,3). In the natural history, the first to appear were integumentary, with the most specific cardiological ones being the closest to diagnosis. The 2-year mortality was 49%, with biomarker RFs and the presence of ≥10 RFs being associated with higher mortality.</div></div><div><h3>Conclusions</h3><div>RFs proved highly prevalent among patients with CA and substantially preceded disease diagnosis. RF burden was associated with prognosis in the follow-up of ATTR patients.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 2","pages":"Pages 61-68"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020625000063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and objectives
Red flags (RF) are typical cardiac and extracardiac manifestations that may precede the definitive diagnosis of cardiac amiloidosis (CA) by several years, playing a pivotal role in the early diagnosis of the disease. The principal aim of the research was to determine the chronology of onset of RF throughout the natural history of CA as well as its prognostic influence.
Patients and methods
Observational, retrospective inquiry of consecutive patients with a definitive diagnosis of CA in a terciary hospital centre in Ciudad Real (Spain) between February 2016 and December 2023. We defined 21 RF and 3 adverse clinical events, establishing the date of occurrence of each of them.
Results
102 patients (81,6 ± 7,7 years; 84,3% males) with a diagnosis of CA (89,2% TTR; 10,8% AL) were included. The prevalence of RF was very high (8,4 ± 2,3). In the natural history, the first to appear were integumentary, with the most specific cardiological ones being the closest to diagnosis. The 2-year mortality was 49%, with biomarker RFs and the presence of ≥10 RFs being associated with higher mortality.
Conclusions
RFs proved highly prevalent among patients with CA and substantially preceded disease diagnosis. RF burden was associated with prognosis in the follow-up of ATTR patients.